Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.39 |
| ▸ | WNT1 | P04628 | 6/20 | 0.39 |
| ▸ | CLK2 | P49760 | 5/20 | 0.39 |
| ▸ | CLK3 | P49761 | 5/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20786506 | 0.88 | LRRK2 (0.42) | LRRK2MAPK1DYRK1AWNT1CLK2 | |
| SCHEMBL20786572 | 0.86 | DYRK1A (0.42) | MAPK1DYRK1AWNT1CLK2CLK3 | |
| SCHEMBL20786113 | 0.85 | MAPK1 (0.45) | LRRK2MAPK1DYRK1AWNT1CLK2 | |
| SCHEMBL22277954 | 0.85 | DYRK1A (0.43) | LRRK2MAPK1DYRK1AWNT1CLK2 | |
| SCHEMBL22264165 | 0.85 | AXL (0.50) | LRRK2NTRK1DYRK1AWNT1GSK3B | |
| SCHEMBL22264352 | 0.84 | WNT1 (0.38) | LRRK2MAPK1DYRK1AWNT1CLK2 | |
| SCHEMBL20786501 | 0.83 | WNT1 (0.39) | MAPK1NTRK1DYRK1AWNT1CLK2 | |
| SCHEMBL22264195 | 0.81 | HDAC6 (0.47) | LRRK2MAPK1DYRK1AWNT1CLK2 | |
| SCHEMBL20786346 | 0.78 | MAPK1 (0.40) | MAPK1 | |
| SCHEMBL20786026 | 0.77 | MAPK1 (0.46) | LRRK2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242334-B2 | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | JS INNOPHARM (SHANGHAI) LTD. (CN) | 2022-02-08 | — | — | US | claimed |
| US-20200239438-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2020-07-30 | — | — | US | claimed |
| US-11242334-B2 | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | JS INNOPHARM (SHANGHAI) LTD. (CN) | 2022-02-08 | — | — | US | disclosed |
| US-11242334-B2 | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | JS INNOPHARM (SHANGHAI) LTD. (CN) | 2022-02-08 | — | — | US | disclosed |
| US-20200239438-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2020-07-30 | — | — | US | disclosed |
| US-20200239438-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239438-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | MAP3K20, MAP3K19, MAP3K1 | LRRK2 635/4885MAPK1 40/4885NTRK1 706/4885 |
| US-11242334-B2 | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | MAP3K20, MAP3K19, MAP3K1 | LRRK2 635/4885MAPK1 40/4885NTRK1 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.